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Abstract
Ductal carcinoma in situ (DCIS) is encountered much more
frequently in the screening population compared to the sympto-
matic setting. The behaviour of DCIS is highly variable and this
presents difficulties in choosing appropriate treatment strategies
for individual cases. This review discusses the current data on the
frequency and rate of progression of DCIS, the value and
limitations of clinicopathological and biological variables in predict-
ing disease behaviour and suggests strategies to develop more
robust means of predicting progression of DCIS.
Introduction
Ductal carcinoma in situ (DCIS) is a neoplastic proliferation
of cells within the ductal-lobular structures of the breast that
has not penetrated the myoepithelial-basement membrane
interface. In the symptomatic setting, DCIS accounts for 3%
to 5% of cancers, although with the advent of population
based screening it now represents approximately 20% of
breast cancers detected [1,2].
Epidemiological, histopathological and genetic studies have
provided compelling evidence to support the concept that
DCIS represents the precursor of invasive carcinoma in the
majority of cases. In recent years, this ‘model of progression’
of breast cancer has been further refined with the recognition
and characterisation of earlier precursor lesions, such as
atypical ductal hyperplasia and the columnar cell lesions [3].
Because the aim of screening is to detect and treat disease
in its early stages in order to prevent life-threatening disease,
it could be argued that DCIS (and maybe even earlier lesions)
represents the ideal target in a strategy to prevent invasive
breast cancer.
This makes the assumption that all DCIS will inevitably
progress to invasive carcinoma; however, much about the
behaviour of DCIS is still poorly understood because
opportunities to study its natural history are limited. Over
recent years, large clinical trials and follow-up on several
important studies in which patients received diagnostic
biopsy alone as treatment for their DCIS have provided
further insight into the behaviour of this disease. The latter
studies, which are biased towards lower-grade lesions, show
that, untreated, up to 50% of DCIS lesions progress to
invasive disease, and that the time for progression may be up
to four decades [4,5]. Conversely, this also indicates that half
of these lesions do not progress to invasive disease within a
woman’s lifetime. The challenge is to define better ways of
quantifying the risk of progression for individual lesions in
order to better tailor treatment decisions.
This review aims to present available data regarding the
frequency and rate of progression of DCIS, the value and
limitations of clinicopathological and biological character-
istics in predicting progression and suggests future strategies
to help more clearly define disease potential and inform
treatment decisions.
Clinicopathological variables and relation to
progression
DCIS is a heterogeneous disease varying in clinical presen-
tation, morphology and behaviour. In an attempt to reflect this
heterogeneity, several histopathological classification
systems have been proposed. These are based on nuclear
morphology, growth pattern, cytonuclear differentiation and
the presence or absence of necrosis, in various combina-
tions. Some of these classification systems provide poor
reproducibility, thereby limiting their clinical practice [6];
however, others give more acceptable levels of reproducibility
and have been shown to be clinically relevant. The Van Nuys
classification system is based on nuclear grade and necrosis,
yielding three subgroups of DCIS – non-high-grade without
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necrosis, non-high-grade with necrosis and high-grade with
or without necrosis – that show an association both with local
recurrence and disease-free survival [7]. The classification
system recommended by the National Coordinating Group
for Breast Screening Pathology in the United Kingdom [8]
classifies the disease into three groups on the basis of cyto-
nuclear features, with low-grade DCIS being composed of
small regular cells, often showing a cribriform or micro-
papillary architecture. High-grade DCIS is composed of
large, pleomorphic cells with frequent mitotic figures, often
having a solid architecture and associated necrosis. Inter-
mediate-grade DCIS shows nuclear features intermediate
between low- and high-grade DCIS. This classification
system has also shown clinical relevance, with high-grade
DCIS exhibiting a higher frequency of recurrence than low-
grade DCIS [9].
Careful analysis of large series of cases is essential to
establish accurate information on disease behaviour. In the
Van Nuys series of 866 DCIS patients, there were a total of
98 recurrences, 46% invasive and 54% non-invasive, with
the probability of an invasive recurrence at 8 years
calculated to be 6.4% and breast cancer-specific mortality
to be 1.1% [10]. This correlates well with other studies
reporting mortality rates of approximately 1.5% to 2.0% at
10 years [1].
Bijker and colleagues [11] followed up 775 cases of DCIS as
part of a randomised clinical trial of breast conserving surgery
for DCIS with or without radiotherapy. Recurrence was
detected in 125 cases at a median follow-up of 5.4 years: 65
developed recurrent DCIS whilst 60 developed invasive
breast cancer. In addition to histological type (nuclear grade,
architecture and necrosis), other factors found to be related
to the rate of recurrence included young patient age, mode of
presentation with recurrence being more common in
symptomatically detected lesions, extent of disease and
margin status. Radiotherapy reduced the risk of recurrence
compared to local excision alone, although recurrence was
still high in patients with involved or not-stated margins,
supporting previous studies emphasising the importance of
margin status [12]. Interestingly, whereas intermediate- and
high-grade DCIS showed significantly higher risk of recurrent
DCIS compared to low-grade DCIS, the risk of recurrence as
invasive disease was independent of DCIS grade. The
outcome of the invasive disease differed markedly between
the grades, however, with the risk of distant metastasis and
death being significantly higher in recurrences secondary to
high-grade DCIS [11]. It has previously been shown that the
grade of DCIS corresponds to the grade of subsequent
invasive carcinoma [13] and together with genetic studies
showing different patterns of chromosomal alterations in
DCIS and invasive carcinomas of different grades [14] these
findings support the proposal that different grades of DCIS
represent distinct disease entities that give rise to different
pathways of disease evolution.
In view of these data, it could be argued that treatment of
DCIS should focus particularly on preventing recurrence in
high-grade DCIS, since this is most likely to progress to life-
threatening disease. However, several studies that report the
long-term follow-up of patients with DCIS treated with biopsy
alone have been important in highlighting the progression
potential of lower-grade lesions.
Betsill and colleagues [15] reported on the outcome of 10
patients with low-grade DCIS treated with biopsy alone with
a mean follow-up of 21.6 years, and found that 7 had
developed invasive carcinoma at an average interval of
9.7 years (range of 7 to 30 years). In the most recent report
from the long-term follow-up study of Page and colleagues
[4] in which 28 women with small low-grade DCIS were
treated with biopsy alone, 11 women developed invasive
breast cancer (39.3%). Of these, 7 were diagnosed within
10 years of their biopsy, 1 within 12 years and 3 over 23 to
42 years. Five of the 11 women who developed invasive
carcinoma died of metastatic disease, with a mean follow-up
of 31 years. In all cases, the invasive carcinoma developed in
the same quadrant of the same breast that the biopsy had
been taken, supporting the proposal that this represents
disease progression rather than de novo disease.
Comparable findings come from the Nurses Health Study [5],
which showed that of 13 patients with DCIS treated by
biopsy alone, 10 developed recurrent disease: 6 developed
invasive carcinoma and 4 developed recurrent in situ disease.
Invasive carcinoma developed in patients with DCIS of all
grades, including 2 of 6 with low-grade disease (at 5 and
18 years post-biopsy), 2 of 6 intermediate-grade DCIS (at 5
and 16 years post-biopsy) and 2 of 3 with high-grade DCIS
(at 4 and 5 years post-biopsy). Taken together, these studies
suggest that whilst progression to invasive disease is more
rapid in high-grade DCIS, all grades have significant potential
to progress.
A much lower recurrence rate was reported by Eusebi and
colleagues [16], who found 11 of 80 women with DCIS
treated with biopsy alone developed invasive carcinoma at a
mean follow-up of 17.5 years. This is likely to reflect the
inclusion of a proportion of cases categorised as pure clinging
DCIS. In the report from Bijker and colleagues [11], an
analysis of recurrence rate in relation to histological subtype of
low-grade DCIS revealed that none of 59 cases of clinging
DCIS developed recurrence, in contrast to low-grade
cribriform lesions, which exhibited similar recurrence rates to
high grade DCIS. To reflect this very low risk of recurrence
and progression, clinging DCIS is now categorised under the
heading of ‘flat epithelial atypia’, and this illustrates the value of
such long-term studies to help refine diagnostic categories.
Biological variables and relation to prognosis
Biological and genetic studies have aimed to refine the
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basis of pathological features alone. For many of these
studies there are confounding factors that make interpretation
complex, for example, the effect of disease extent and margin
involvement.
Of the biological markers most extensively analysed, possibly
one of the studies that most effectively controls for these
factors is that of Cornfield and colleagues [17]. They
analysed 151 cases of DCIS detected by mammography or
as an incidental finding in a benign biopsy (suggesting limited
disease extent); all were treated by breast conserving surgery
alone and confirmed clear of margins. They found recurrence
in 42 cases (27.8%) between 11 and 97 months following
surgery and analysed disease behaviour in relation to
expression of oestrogen receptor, progesterone receptor,
p53, Ki-67, HER2, bcl-2 and p21 in addition to conventional
histopathological parameters. Whilst correlations between
biological markers were noted (e.g., significant negative
correlation between HER2 and oestrogen receptor, and
between HER2 and bcl-2), none of the biological markers
exhibited any association with disease recurrence, either in
univariate or multivariate analysis [17].
Other workers have reported associations between some of
these markers and disease recurrence. Ringberg and
colleagues [18] found high Ki-67, high p53 and reduced
bcl-2 to be associated with recurrence in univariate analysis,
although in multivariate analysis including tumour grade and
growth pattern none reached statistical significance. This is
largely in agreement with other reports that show a
relationship between grade of DCIS and biological factors,
such as p53 mutation [19].
Whilst these studies suggest that biological markers do not
enhance the predictive power of histopathological factors,
Barnes and colleagues [20] have recently reported the
independent prognostic value of HER4 expression in DCIS.
HER4 has been shown to modulate HER2 signalling leading
to a reduction in cell proliferation [21]. In a retrospective
analysis, this group showed that HER2 and HER3 expression
was significantly associated with disease recurrence whereas
HER4 expression was significantly less frequent in disease
that recurred. Expression of HER4 in the absence of HER2
led to a highly significant disease-free survival advantage, and
the prognostic significance of HER4 expression was
maintained in multivariate analysis that included disease
grade and margin status. Whether HER4 expression can
contribute to the recognition of a subgroup of DCIS with
better prognosis remains to be established and will require
larger long-term studies and, in particular, greater numbers of
lower grade lesions.
Another approach trying to define factors that will predict
behaviour of DCIS has been to identify changes in gene or
protein expression associated with the transition to invasive
disease. Ma and colleagues [22] used laser capture
microdissection of in situ and invasive disease followed by
cDNA microarray analysis to generate a gene expression
profile associated with disease progression. The major
differences in gene expression profile were seen in relation to
different grade invasive tumours rather than disease stage
and generally disease of different stages from the same
patient clustered more closely than stage-specific disease.
One exception was in high grade DCIS where cluster
analysis identified a set of 29 genes that was more highly
expressed in the matched invasive component compared to
the DCIS, suggesting they may be related to progression.
The gene set included genes involved in cell cycle control,
centrosomal function and DNA repair, and one gene, RRM2,
which has been linked to metastatic potential. As yet, the
value of such a gene profile has not been established, though
data from similar studies comparing invasive and matched
metastatic carcinomas suggest a common predictive gene
signature could be elusive [23].
A recent report has proposed that the natural history of
different DCIS subtypes relates to the pattern of development
of DCIS within the breast lobe [24]. This hypothesis, based on
extensive review of large two- and three-dimensional
histological sections of DCIS, suggests that DCIS may appear
as unifocal, multifocal or diffuse disease due to involvement of
individual terminal ductal-lobular units, several distant terminal
ductal-lobular units or involvement of larger ducts. They found
that low-grade DCIS tends to be multifocal, intermediate
grade unifocal and diffuse with duct neogenesis almost
exclusively high grade and this has an impact on recurrence.
This study also associated the diffuse neogenetic DCIS with
expression of Tenascin-C in the stroma, a reflection of the
remodelling occurring in high grade disease. Such changes in
the microenvironment may influence tumour progression.
Alterations in the myoepithelial cell population and the stromal
cells around DCIS have been described that could influence
initiation of invasion [25-27]. However, further functional
studies and analysis of larger case series will be required to
determine the importance of such phenotypic changes.
Conclusion
The studies to date indicate that DCIS of all grades has the
potential to progress, though high-grade lesions progress
more rapidly than lower grade lesions and are more likely to
lead to metastatic disease and death. Long-term follow-up
studies have further stratified disease behaviour and led to
the identification of lesions that exhibit significantly lower
progression potential, such as flat cell atypia, and it is clear
that these should be treated differently to DCIS. Given the
different behaviour of low and high grade DCIS, both in terms
of leading to life-threatening disease and in the time for
evolution of the disease, it would appear warranted to tailor
treatment more closely to disease type, with less aggressive
therapy for low grade lesions. However, the challenge
remains to accurately identify the small number of low-grade
lesions likely to progress in order to provide the most
Available online http://breast-cancer-research.com/content/8/2/204appropriate treatment without over-treating the vast majority
of patients with lesions that will be cured by breast
conserving surgery alone.
Thus far, biological studies have not had a significant impact
on predicting disease behaviour, although continued efforts,
informed by functional (i.e., in vitro and animal models) and
genetic studies, together with greater understanding afforded
by studies of disease development as described in [24], and
careful analysis of large clinical trials should help to better
define disease behaviour and define distinct subgroups of
DCIS with prognostic significance. Because the events being
measured are rare, that is, recurrence, invasion and
metastasis, particularly for low grade lesions, meaningful
studies to test the predictive power of new approaches and
biological markers will require analysis on large numbers of
cases with follow-up, which is most likely to be achieved
through material gained from clinical trials.
Competing interests
The author declares that they have no competing interests.
References
1. Ernster VL, Barclay J, Kerlikowske K, Wilkie H, Ballard-Barbash R:
Mortality among women with ductal carcinoma in situ of the
breast in the population-based surveillance, epidemiology
and end results program. Arch Intern Med 2000, 160:953-958.
2. Van Dongen JA, Fentiman IS, Harris JR, Holland R, Peterse JL,
Salvadori B, Stewart HJ: In situ breast cancer: the EORTC con-
sensus meeting. Lancet 1989, ii:25-27.
3. Schnitt SJ: Flat epithelial atypia - classification, pathologic
features and clinical significance. Breast Cancer Res 2003, 5:
263-268.
4. Saunders ME, Schuyler PA, Dupont WD, Page DL: The natural
history of low grade ductal carcinoma in situ of the breast in
women treated by biopsy only revealed over 30 years of long-
term follow-up. Cancer 2005, 103:2481-2484.
5. Collins LC, Tamimi RM, Baer HJ, Connoly JL, Colditz GA, Schnitt
SJ:  Outcome of patients with ductal carcinoma in situ
untreated after diagnostic biopsy. Results from the Nurses’
Health Study. Cancer 2005, 103:1778-1784.
6. Van Dongen JA, Holland R, Peterse JL, Fentiman IS, Lagios MD,
Millis RR, Recht A: Ductal carcinoma in situ of the breast:
second EORTC consensus meeting. Eur J Cancer 1992, 28:
626-629.
7. Silverstein MJ, Lagios MD, Craig PH, Waisman JR, Lewinsky BS,
Colburn WJ, Poller DN: A prognostic index for ductal carci-
noma in situ of the breast. Cancer 1996, 77:2267-2274.
8. National Coordinating Group for Breast Screening Pathology:
Guidelines for Pathology Reporting in Breast Cancer Screening.
3rd edition. Sheffield: NHSBSP Publications; 2005.
9. Badve S, A’Hern RP, Ward AM, Millis RR, Pinder SE, Ellis IO,
Gusterson BA, Sloane JP: Prediction of local recurrence of
ductal carcinoma in situ of the breast using five histological
classifications: a comparative study with long follow-up. Hum
Pathol 1998, 29:915-923.
10. Skinner KA, Silverstein MJ: The management of ductal carci-
noma in situ of the breast. Endocr Relat Cancer 2001, 8:33-45.
11. Bijker N, Peterse JL, Julien J-P, Fentimen IS, Duval C, Di Palma S,
Simony-Lafontaine J, de Mascarel I, van de Vijver M: Risk factors
for recurrence and metastasis after breast conserving
therapy for ductal carcinoma in-situ: analysis of European
organisation for research and treatment of cancer trial 10853.
J Clin Oncol 2001, 19:2263-2271.
12. Silverstein MJ, Lagios MD, Groshen S, Waisman JR, Lewinsky
BS, Martino S, Gamagami P, Colburn WJ: The influence of
margin width on local control of ductal carcinoma in situ of
the breast. N Eng J Med 1999, 340:1455-1461.
13. Millis RR, Ryder K, Fentiman IS: Ductal carcinoma in situ and
prognosis in invasive mammary carcinoma. Breast Cancer
Res Treat 2004, 84:197-198.
14. Simpson PT, Reis-Filho JS, Gale T, Lakhani SR: Molecular evolu-
tion of breast cancer. J Pathol 2005, 205:248-254.
15. Betsill WLJ, Rosen PP, Lieberman PH, Robbins GF: Intraductal
carcinoma. Long tern follow-up after treatment by biopsy
alone. J Am Med Assoc 1978, 239:1863-1867.
16. Eusebi V, Feudale E, Foschini MP, Micheli A, Conti A, Riva C, Di
Palma S, Rilke F: Long-term follow-up of in-situ carcinoma of
the breast. Semin Diag Pathol 1994, 11:223-235.
17. Cornfield DB, Palazzo JP, Schwartz GF, Goonewardene SA,
Kovatich AJ, Chervoneva I, Hyslop T, Schwarting R: The prog-
nostic significance of multiple morphologic features and bio-
logic markers in ductal carcinoma in situ of the breast. A
study of a large cohort of patients treated with surgery alone.
Cancer 2004, 100:2317-2327.
18. Ringberg A, Anagnostaki L, Anderson H, Idvall I, Ferno M: Cell
biological factors in ductal carcinoma in situ (DCIS) of the
breast – relationship to ipsilateral local recurrence and
histopathological characteristics. Eur J Cancer 2001, 37:1514-
1522.
19. Done SJ, Eskandarain S, Bull S, Redson M, Andrulis IL: p53 mis-
sense mutation in microdissected high grade ductal carci-
noma in situ of the breast. J Natl Cancer Inst 2001,  93:
700-704.
20. Barnes NLP, Khavari S, Boland GP, Cramer A, Knox WF,
Bundred NJ: Absence of HER4 expression predicts recurrence
of ductal carcinoma in situ of the breast. Clin Cancer Res
2005, 11:2163-2168.
21. Sartor CI, Zhou H, Kozlowska E, Guttridge K, Kawata E, Caskey
L, Harrelson J, Hynes N, Ethier S, Calvo B, Earp HS: HER4 medi-
ates ligand dependent antiproliferative and differentiation
responses in human breast cancer cells. Mol Cell Biol 2001,
21:4265-4275.
22. Ma XJ, Salunga R, Tuggle JT, Gaudet J, Enright E, McQuary P,
Payette T, Pistone M, Stecker K, Zhang BM, et al.: Gene expres-
sion profiles of breast cancer progression. Proc Natl Acad Sci
USA 2003, 100:5974-5979.
23. Weigelt B, Wessels LFA, Bosma AJ, Glas AM, Nuyten DSA, He
YD, Dai H, Peterse JL, van’t Veer LJ: No common denominator
for breast cancer lymph node metastasis. Br J Cancer 2005,
93:924-932.
24. Tot T: DCIS, cytokeratins and the theory of the sick lobe. Vir-
chows Arch 2005, 447:1-8.
25. Adams M, Jones JL, Walker RA, Pringle JH, Bell SC: Altered
Tenascin-C isoform expression in invasive and pre-invasive
breast cancer. Cancer Res 2002, 62:3289-3297.
26. Allinen M, Beroukhim R, Cal LI, Brennan C, Lahti-Domenici J,
Huang H, Porter D, Hu M, Chin L, Richardson A, et al.: Molecular
characterisation of tumour microenvironment in breast
cancer. Cancer Cell 2004, 6:17-32.
27. Nielsen BS, Rank F, Lopez JM, Balbin M, Vizoso F, Lund LR, Dano
K, Lopez-Otin C: Collagenase-3 expression in breast myofi-
broblasts as a molecular marker of transition of ductal carci-
noma in-situ lesions to invasive ductal carcinomas. Cancer
Res 2001, 61:7091-7100.
Breast Cancer Research    Vol 8 No 2 Jones
Page 4 of 4
(page number not for citation purposes)
This article is part of a review series on 
Overdiagnosis and overtreatment of breast cancer, 
edited by Nick E Day, Stephen Duffy and Eugenio Paci.
Other articles in the series can be found online at
http://breast-cancer-research.com/articles/
review-series.asp?series=BCR_Overdiagnosis